This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
G1 Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
G1 Therapeutics has been growing earnings at an average annual rate of 9.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 38.8% per year.
Belangrijke informatie
9.2%
Groei van de winst
14.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 38.8% |
Rendement op eigen vermogen | -182.1% |
Nettomarge | -76.9% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Opbrengsten en kosten
Hoe G1 Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 58 | -45 | 61 | 29 |
31 Mar 24 | 84 | -31 | 65 | 35 |
31 Dec 23 | 83 | -48 | 72 | 43 |
30 Sep 23 | 78 | -71 | 80 | 52 |
30 Jun 23 | 89 | -78 | 88 | 63 |
31 Mar 23 | 57 | -126 | 96 | 72 |
31 Dec 22 | 51 | -148 | 101 | 83 |
30 Sep 22 | 47 | -154 | 101 | 86 |
30 Jun 22 | 28 | -171 | 101 | 87 |
31 Mar 22 | 24 | -171 | 100 | 85 |
31 Dec 21 | 31 | -148 | 96 | 75 |
30 Sep 21 | 42 | -134 | 98 | 72 |
30 Jun 21 | 64 | -103 | 92 | 69 |
31 Mar 21 | 60 | -95 | 81 | 68 |
31 Dec 20 | 45 | -99 | 69 | 72 |
30 Sep 20 | 29 | -109 | 57 | 81 |
30 Jun 20 | 2 | -130 | 50 | 127 |
31 Mar 20 | 0 | -130 | 44 | 109 |
31 Dec 19 | 0 | -122 | 41 | 88 |
30 Sep 19 | 0 | -111 | 35 | 135 |
30 Jun 19 | 0 | -99 | 29 | 70 |
31 Mar 19 | 0 | -89 | 23 | 53 |
31 Dec 18 | 0 | -85 | 19 | 70 |
30 Sep 18 | 0 | -78 | 14 | 0 |
30 Jun 18 | 0 | -74 | 11 | 0 |
31 Mar 18 | 0 | -68 | 9 | 17 |
31 Dec 17 | 0 | -65 | 7 | 54 |
30 Sep 17 | 0 | -60 | 6 | 0 |
30 Jun 17 | 0 | -52 | 5 | 0 |
31 Mar 17 | 0 | -45 | 4 | 0 |
31 Dec 16 | 0 | -35 | 5 | 0 |
31 Dec 15 | 1 | -22 | 3 | 0 |
31 Dec 14 | 1 | -7 | 3 | 0 |
Kwaliteitswinsten: GTHX is currently unprofitable.
Groeiende winstmarge: GTHX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: GTHX is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.
Versnelling van de groei: Unable to compare GTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: GTHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Rendement op eigen vermogen
Hoge ROE: GTHX has a negative Return on Equity (-182.05%), as it is currently unprofitable.